<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04993768</url>
  </required_header>
  <id_info>
    <org_study_id>TPN-101-PSP-201</org_study_id>
    <nct_id>NCT04993768</nct_id>
  </id_info>
  <brief_title>A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)</brief_title>
  <official_title>A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Transposon Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Transposon Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2a study to assess the safety and tolerability of TPN-101 patients with PSP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a multi-center, randomized, double-blind, placebo-controlled parallel-group,&#xD;
      4-arm study with an open-label treatment phase in patients with PSP. This study includes a&#xD;
      6-week Screening Period, a 24-week Double-blind Treatment Period, a 24-week Open label&#xD;
      Treatment Period, and a Follow-up Visit 4 weeks post treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">July 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety and tolerability of TPN-101 in patients with progressive supranuclear palsy (PSP)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Incidence and severity of spontaneously reported treatment-emergent adverse events (TEAEs) associated with TPN-101 v. placebo administered for up to 48 weeks in patients with PSP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the pharmacokinetics of TPN-101 as measured by concentrations of TPN-101 in plasma and cerebrospinal fluid (CSF)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the pharmacodynamic effect of TPN-101 on neurodegeneration as measured by changes in the levels of CSF and blood neurofilament light (NfL)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the clinical effect of TPN-101 as measured by changes in score on the Progressive Supranuclear Palsy Rating Scale (PSPRS)</measure>
    <time_frame>48 weeks</time_frame>
    <description>The PSPRS is comprised of 28 items in six categories: daily activities (by history), behavior, bulbar, ocular motor, limb motor and gait/midline. Scores range from 0 to 100, each item is graded 0-2 (six items) or 0-4 (22 items), with lower scores indicating better clinical and functional status.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <arm_group>
    <arm_group_label>TPN-101, Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TPN-101, Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TPN-101, Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPN-101, 100 mg/day</intervention_name>
    <description>100 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).</description>
    <arm_group_label>TPN-101, Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPN-101, 200 mg/day</intervention_name>
    <description>200 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).</description>
    <arm_group_label>TPN-101, Dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPN-101, 400 mg/day</intervention_name>
    <description>400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).</description>
    <arm_group_label>TPN-101, Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of probable progressive supranuclear palsy (PSP)&#xD;
&#xD;
          2. Presence of PSP symptoms for less than 5 years&#xD;
&#xD;
          3. Body weight range of ≥ 41 kg (90 lbs) to ≤ 118 kg (260 lbs)&#xD;
&#xD;
          4. Has a reliable caregiver to accompany the patient to all study visits.&#xD;
&#xD;
          5. Score ≥ 18 on the Mini Mental State Exam (MMSE) at Screening&#xD;
&#xD;
          6. Patient must reside outside a skilled nursing facility or dementia care facility at&#xD;
             the time of Screening, and admission to such a facility must not be planned. Residence&#xD;
             in an assisted living facility is allowed&#xD;
&#xD;
          7. If patient is receiving coenzyme Q10, levodopa/carbidopa, levodopa/ benserazide, a&#xD;
             dopamine agonist, catechol-o-methyltransferase inhibitor, other Parkinson's disease&#xD;
             medication, or memantine with or without acetylcholinesterase inhibitors for&#xD;
             cognition, the dose must have been stable for at least 30 days prior to Screening and&#xD;
             must remain stable for the duration of the study. No such medication may be initiated&#xD;
             during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients must not meet any of the following criteria:&#xD;
&#xD;
          1. Presence of other significant neurological or psychiatric disorders including (but not&#xD;
             limited to) Alzheimer's disease; dementia with Lewy bodies; prion disease; Parkinson's&#xD;
             disease (which has not subsequently been revised to PSP); amyotrophic lateral&#xD;
             sclerosis or other motor neuron disease; multiple sclerosis; any psychotic disorder;&#xD;
             severe bipolar or unipolar depression; prior history of a suicide attempt or current&#xD;
             suicidal thoughts or behavior that are believed to represent a safety risk as&#xD;
             indicated by a &quot;yes&quot; response to Question 2 of the C-SSRS; seizure; brain tumor or&#xD;
             other space-occupying lesion; history of stroke; or history of severe head injury&#xD;
             within the past 20 years&#xD;
&#xD;
          2. History of significant brain abnormality, including, but not limited to, prior&#xD;
             hemorrhage or infarct, cerebral contusion, encephalomalacia, aneurysm, vascular&#xD;
             malformation, subdural hematoma (SDH), hydrocephalus, or space-occupying lesion (e.g.,&#xD;
             abscess or brain tumor such as meningioma). If there is history or evidence on&#xD;
             neurologic exam suggesting possible SDH, patients should be fully evaluated, including&#xD;
             MRI if indicated, to exclude significant, new SDH&#xD;
&#xD;
          3. Presence of cerebellar ataxia, choreoathetosis, early symptomatic autonomic&#xD;
             dysfunction, or moderate to severe resting tremor, responsive to levodopa&#xD;
&#xD;
          4. Known history of serum or plasma progranulin level less than one standard deviation&#xD;
             below the normal patient mean for the laboratory performing the assay&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>41 Years</minimum_age>
    <maximum_age>86 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jay Soto</last_name>
    <phone>310-261-5312</phone>
    <email>clinicaltrials@transposonrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders Center of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart Isaacson, MD</last_name>
      <phone>561-392-1818</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Berry, MD, MPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quest Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Ellenbogen, DO, MPH</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

